Engineered immune cells from cord blood take on tough lymphoma
NCT ID NCT07164560
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial is testing a new treatment for people with relapsed or refractory peripheral T-cell lymphoma, a rare and aggressive blood cancer. The therapy uses immune cells (NK cells) from donated umbilical cord blood that are genetically modified to recognize and attack cancer cells. The study will enroll 45 adults aged 18 to 75 to check if the treatment is safe and to find the best dose.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- umbilical cord blood-derived CAR-NK cells targeting TRBC1/2
- What this could lead to
- If successful, this could offer a new treatment option for patients with hard-to-treat T-cell lymphoma who have not responded to prior therapies.
- What could go wrong
- This is an early Phase 1 trial with only 45 participants, so safety and effectiveness are not yet proven. There may be side effects like infusion reactions or infections, and the therapy may not work for everyone.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ANAPLASTIC LARGE CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
2nd Affiliated Hospital,School of Medicine,Zhejiang University
RECRUITINGHangzhou, Zhejiang, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple blood test spot lymphoma earlier?
- New drug cocktail shows promise for tough lymphomas
- Promising combo tackles rare blood cancer in chinese patients
- New drug cocktail aims to tackle rare blood cancer
- New pill shows promise for rare blood cancer in Late-Stage trial
- New drug combo shows promise for rare lymphoma in Real-World study